Online inquiry

IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12783MR)

This product GTTS-WQ12783MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets NOTCH2&NOTCH3 gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001200001.2; NM_000435.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4853; 4854
UniProt ID Q04721; Q9UM47
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12783MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1796MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ADCT-402
GTTS-WQ2214MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ8466MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HTI-1088
GTTS-WQ7865MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ6425MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CT-P22
GTTS-WQ7839MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ13820MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-10987
GTTS-WQ6538MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CX-191
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW